ERY 974

Drug Profile

ERY 974

Alternative Names: Anti glypican3/CD3 bispecific antibody; ERY974; T cell redirecting bispecific antibody - Chugai

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Glypican 3 inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 06 Oct 2017 Preclinical pharmacodynamics data in Solid tumours released by Chugai Pharmaceutical
  • 01 Aug 2016 Phase-I clinical trials in Solid tumours in USA (IV) (NCT02748837)
  • 03 Jun 2016 Chugai plans a phase I trial for glypican3-positive Solid tumours
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top